36 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22666 | RECIST v1.1 | Ahmad Hussein Awada | Multiple | Genoscience Pharma | GNS561-CL-I-Q-0211 | Trial closed for recruitment | New Title: Phase 1/2a study to evaluate the safety, activity, and pharmacokinetics of escalating doses of GNS561 in patients with primary or secondary liver cancer. (Old Title: Phase 1/2a study to evaluate the safety, activity, and pharmacokinetics of escalating doses of GNS561 in patients with primary liver cancer) |
ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22625 | RECIST 1.1, after standard trerapy | Ahmad Hussein Awada | Multiple | Lilly | I7W-MC-JQBA | Trial closed | A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22650 | vaccine, diarrhea, clostridium | Multiple | Pfizer | IJB_2672 | Trial closed | A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older | 3 | 3 | |||
| 22850 | Metastatic, any tumors | Solid tumors | Institut Jules Bordet | IJB_2728 | Trial open for recruitment | Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention | |||||
| 22657 | Metastatic, Biopsy mandatory | Nuria Kotecki | Multiple | Lilly | IJB_2732 | Trial closed | A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors | Nuria.Kotecki@hubruxelles.be | 1/1b | 1 | |
| 22662 | second line, RECIST 1.1, Biopsy | Philippe Aftimos | Multiple | Incyte Corporate | INCAGN1876-201 | Trial closed | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | philippe.aftimos@hubruxelles.be | 1 | 1 | |
| 22640 | Metastatic, Biopsy mandatory | Christiane Jungels | Multiple | Incyte Corporate | INCB 01158-203 | Trial closed | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors. (INCB01158-203) | christiane.jungels@hubruxelles.be | 1 | 1 | |
| 22655 | Any line | Ahmad Hussein Awada | Solid tumors | Incyte Corporate | INCB59872-101 | Trial closed | A Phase 1/2, Open-Label, Dose-Escalation / Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies | ahmad.awada@hubruxelles.be | 1/2 | 1 | |
| 22849 | Be a parent or close relative of a child between the ages of 3 and 18 confronted with parental cancer, any tumors | Solid tumors | Intervention destinée aux parents | Trial open for recruitment | L'enfant face au cancer d'un parent: une étude randomisée évaluant l'efficacité d'une intervention psychologique destinée à soutenir la parentalité | ||||||
| 22669 | Metastatic, Biopsy mandatory | Christiane Jungels | Multiple | Merus | MCLA-158-CL01 | Trial open for recruitment | Phase 1 dose escalation and cohort expansion study evaluating single-agent MCLA-158 in metastatic colorectal cancer and other advanced solid tumors | christiane.jungels@hubruxelles.be | 1 | 1 | |
| 22826 | first line, RECIST 1.1 | Alain Hendlisz | Colon | Roche | MO29112 | Trial closed | A multi-centre randomized clinical trial of Biomarker-Driven maintenance treatment for first-line metastatic colorectal cancer (MODUL) | alain.hendlisz@hubruxelles.be | 2 | 2 | |
| 29693 | Francesco Sclafani | Multiple | Seagen | Mountaineer-03 | Trial open for recruitment | An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer(SGNTUC-029 - Mountaineer-03) | francesco.sclafani@hubruxelles.be | 3 | 3 | ||
| 22675 | Any line/RECIST v1.1/Eligible for platinium salt chemotherapy | Nuria Kotecki | Multiple | Onxeo | OX2016-203-01 | Trial closed | An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors | Nuria.Kotecki@hubruxelles.be | 1 | 1 | |
| 22741 | Clinical/radiological evaluation compatible with stage III colon adenocarcinoma. No prior chemotherapy. |
Alain Hendlisz | Colon | Institut Jules Bordet | PePiTA | Trial closed | A BGDO study PePiTA trial : Preoperative chemosensitivity in adjuvant stage III colon cancer | alain.hendlisz@hubruxelles.be | 3 | 3 |